- Home
- APRE
as of 03-09-2026 2:46pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 6.3M | IPO Year: | 2019 |
| Target Price: | $5.50 | AVG Volume (30 days): | 252.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | 37.97 |
| 52 Week Low/High: | $0.55 - $2.76 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -80.06% | Revenue Growth (next year): | -65.95% |
| P/E Ratio: | -0.55 | Index: | N/A |
| Free Cash Flow: | -13572196.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Aprea Therapeutics Inc. (APRE)
President/CEO
Avg Cost/Share
$0.89
Shares
28,100
Total Value
$25,009.00
Owned After
373,720
SEC Form 4
SrVP/CFO/Prin Fin & Acct Ofcr
Avg Cost/Share
$0.89
Shares
5,700
Total Value
$5,073.00
Owned After
33,433
SEC Form 4
SrVP/CFO/Prin Fin & Acct Ofcr
Avg Cost/Share
$1.17
Shares
5,000
Total Value
$5,825.00
Owned After
33,433
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gilad Oren | APRE | President/CEO | Jan 30, 2026 | Buy | $0.89 | 28,100 | $25,009.00 | 373,720 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Jan 30, 2026 | Buy | $0.89 | 5,700 | $5,073.00 | 33,433 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Dec 10, 2025 | Buy | $1.17 | 5,000 | $5,825.00 | 33,433 | |
| Duey Marc | APRE | Director | Dec 10, 2025 | Buy | $1.17 | 21,459 | $24,999.74 | 256,155 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 12, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLNov 12, 2025 · 100% conf.
1D
-3.49%
$1.22
Act: -5.56%
5D
-11.96%
$1.11
Act: -4.76%
20D
-15.53%
$1.06
Act: -25.00%
Aprea Therapeutics, Inc._November 12, 2025 0001781983false00017819832025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 12, 2025 Date of Report (Date of earliest event reported)
Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-39069 84-2246769
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
3805 Old Easton Road Doylestown, PA (Address of principal executive offices) 18902 (Zip Code)
Registrant’s telephone number, including area code: (215) 948-4119 (Former name or former address, if changed since last report): Not applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.001 per share
APRE
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition. On November 12, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 8.01Other Events. On November 12, 2025, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference. Item 9.01Financial Statements and Exhibits. (d) Exhibits.
Exhibit Number
Description
99.1 Press release issued by Aprea Therapeutics, Inc. dated November 12, 2025.
99.2 Corporate Presentation (November 2025).
104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Aprea Therapeutics, Inc.
Dated: November 12, 2025 By: /s/ Oren Gilad
Name: Oren Gilad, Ph.D.
Title: President and Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
Q2 2025 Earnings
8-KAug 12, 2025
Aprea Therapeutics, Inc._August 12, 2025 0001781983false00017819832025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2025 Date of Report (Date of earliest event reported)
Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-39069 84-2246769
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
3805 Old Easton Road Doylestown, PA (Address of principal executive offices) 18902 (Zip Code)
Registrant’s telephone number, including area code: (215) 948-4119 (Former name or former address, if changed since last report): Not applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.001 per share
APRE
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition. On August 12, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 8.01Other Events. On August 12, 2025, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference. Item 9.01Financial Statements and Exhibits. (d) Exhibits.
Exhibit Number
Description
99.1 Press release issued by Aprea Therapeutics, Inc. dated August 12, 2025.
99.2 Corporate Presentation (August 2025).
104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Aprea Therapeutics, Inc.
Dated: August 12, 2025 By: /s/ Oren Gilad
Name: Oren Gilad, Ph.D.
Title: President and Chief Executive Officer
2025 Q1 Q1 2025 Earnings
8-K May 14, 2025
Q1 2025 Earnings
8-KMay 14, 2025
Aprea Therapeutics, Inc._May 14, 2025 0001781983false00017819832025-05-142025-05-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2025 Date of Report (Date of earliest event reported)
Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-39069 84-2246769
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
3805 Old Easton Road Doylestown, PA (Address of principal executive offices) 18902 (Zip Code)
Registrant’s telephone number, including area code: (215) 948-4119 (Former name or former address, if changed since last report): Not applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.001 per share
APRE
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition. On May 14, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 8.01Other Events. On May 14, 2025, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference. Item 9.01Financial Statements and Exhibits. (d) Exhibits.
Exhibit Number
Description
99.1 Press release issued by Aprea Therapeutics, Inc. dated May 14, 2025.
99.2 Corporate Presentation (May 2025).
104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Aprea Therapeutics, Inc.
Dated: May 14, 2025 By: /s/ Oren Gilad
Name: Oren Gilad, Ph.D.
Title: President and Chief Executive Officer
Compare APRE vs Leading Stocks
See how APRE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.